PE20201405A1 - Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante - Google Patents

Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante

Info

Publication number
PE20201405A1
PE20201405A1 PE2020001382A PE2020001382A PE20201405A1 PE 20201405 A1 PE20201405 A1 PE 20201405A1 PE 2020001382 A PE2020001382 A PE 2020001382A PE 2020001382 A PE2020001382 A PE 2020001382A PE 20201405 A1 PE20201405 A1 PE 20201405A1
Authority
PE
Peru
Prior art keywords
cov
sars
recombinant
salmonella enteritidis
strain
Prior art date
Application number
PE2020001382A
Other languages
English (en)
Inventor
Diaz Manolo Clemente Fernandez
Original Assignee
Farm Veterinarios S A C
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=74205468&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20201405(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Farm Veterinarios S A C filed Critical Farm Veterinarios S A C
Priority to PE2020001382A priority Critical patent/PE20201405A1/es
Publication of PE20201405A1 publication Critical patent/PE20201405A1/es
Priority to PCT/PE2021/000006 priority patent/WO2022055375A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/42—Salmonella

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invencion se refiere a una vacuna viva recombinante basada en una cepa de Salmonella enteritidis que expresa la proteina S del virus SARS-CoV-2 en donde la mejor expresion se ha logrado cuando la insercion se encuentra en el plasmido en vez del cromosoma. Asimismo, se refiere a una vacuna que precisa de dicha cepa. Tambien se hace referencia al uso de una cepa de Salmonella enteritidis 3934 (depositada en la Coleccion Espanola de Cultivos Tipo (CECT) con el numero de acceso CECT9332) para el tratamiento de SARS-CoV-2 y al metodo para controlar la infeccion por SARS-CoV-2 mediante la administracion a mamiferos de una vacuna viva recombinante
PE2020001382A 2020-09-09 2020-09-09 Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante PE20201405A1 (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PE2020001382A PE20201405A1 (es) 2020-09-09 2020-09-09 Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante
PCT/PE2021/000006 WO2022055375A1 (es) 2020-09-09 2021-04-09 Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PE2020001382A PE20201405A1 (es) 2020-09-09 2020-09-09 Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante

Publications (1)

Publication Number Publication Date
PE20201405A1 true PE20201405A1 (es) 2020-12-02

Family

ID=74205468

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001382A PE20201405A1 (es) 2020-09-09 2020-09-09 Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante

Country Status (2)

Country Link
PE (1) PE20201405A1 (es)
WO (1) WO2022055375A1 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20171768A1 (es) * 2017-06-12 2017-12-21 Farm Veterinarios S A C Obtencion de una salmonela enteritidis tipo rugosa y sus modificaciones geneticas para uso como vacuna aviar

Also Published As

Publication number Publication date
WO2022055375A1 (es) 2022-03-17

Similar Documents

Publication Publication Date Title
AR109538A1 (es) Vacuna contra la gripe porcina
CL2019002964A1 (es) Vacunas contra el gallid herpesvirus 3 recombinante que codifican antígenos patogénicos aviares heterólogos.
CO2019001044A2 (es) Composición de cannabis
BR112018075440A2 (pt) composições e métodos para prevenir e tratar a infecção por zika vírus
CL2021003211A1 (es) Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018)
EA201391200A1 (ru) Способы и композиции для вакцинации от staphylococcus aureus
AR108829A1 (es) Vacuna contra virus de bronquitis infecciosa
CL2021000485A1 (es) Una cepa mutante de salmonella enteritidis; procedimiento para generar la cepa mutante; vacuna recombinante aviar de salmonella enteritidis, divisional de la solicitud 201903108
PE20230171A1 (es) Vacunas contra el coronavirus y metodos de uso
CO2021017664A2 (es) Péptidos
AR041964A1 (es) Vacuna de vhc que comprende un polinucleotido
CL2021002582A1 (es) Vacunas contra el circovirus porcino tipo 3 (pcv3), su producción y usos
CO2021005066A2 (es) Vacuna de ibv 4/91 con proteína espicular heteróloga
CO2021012074A2 (es) Suministro de β-sarcoglicano mediante vectores de virus adenoasociado y el tratamiento de la distrofia muscular
CL2022000161A1 (es) Vacuna contra la peste porcina africana
CO2020004244A2 (es) Métodos y composiciones para tratar enfermedades pulmonares crónicas
CO2022017989A2 (es) Vacunas para la papilomatosis respiratoria recurrente y métodos para usar estas
PE20201405A1 (es) Vacuna viva recombinante para sars-cov-2 basada en salmonella enteritidis recombinante
UY39378A (es) Vacuna de salmonella para el tratamiento de coronavirus
BR112022006926A2 (pt) Vetor de vírus oncolítico que codifica o polipeptídeo variante de interleucina 2 (vil-2)
PH12020551944A1 (en) Reverse peptide vaccine
EA202191147A1 (ru) Вакцина виб h52 с гетерологичным шиповидным белком
MX2021003660A (es) Composicion inyectable.
DOP2014000215A (es) Virus de la enfermedad de marek modificado y vacunas elaboradas con él
BR112023011605A2 (pt) Uso do peptídeo, método de tratamento de câncer ou infecções virais, e, combinação farmacêutica